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ABSTRACT
Background: Clinical subtypes of mild cognitive impair-
ment (MCI) may represent different underlying aetio-
logies.
Methods: This European, multicentre, memory clinic
based study (DESCRIPA) of non-demented subjects
investigated whether MCI subtypes have different brain
correlates on MRI and whether the relation between
subtypes and brain pathology is modified by age. Using
visual rating scales, medial temporal lobe atrophy (MTA)
(0–4) and white matter hyperintensities (WMH) (0–30)
were assessed.
Results: Severity of MTA differed between MCI subtypes
(p,0.001), increasing from a mean of 0.8 (SD 0.7) in
subjective complaints (n = 77) to 1.3 (0.8) in non-
amnestic MCI (n = 93), and from 1.4 (0.9) in single
domain amnestic MCI (n = 70) to 1.7 (0.9) in multiple
domain amnestic MCI (n = 89). The association between
MCI subtype and MTA was modified by age and mainly
present in subjects .70 years of age. Severity of WMH
did not differ between MCI subtypes (p = 0.21).
However, the combination of MTA and WMH differed
between MCI subtypes (p = 0.02)
Conclusion: We conclude that MCI subtypes may have
different brain substrates, especially in older subjects.
Isolated MTA was mainly associated with amnestic MCI
subtypes, suggesting AD as the underlying cause. In non-
amnestic MCI, the relatively higher prevalence of MTA in
combination with WMH may suggest a different
pathophysiological origin.
Mild cognitive impairment (MCI) refers to cogni-
tive decline in non-demented subjects and is
considered to be a risk state for Alzheimer’s disease
(AD).1–3 However, not all subjects with MCI will
develop AD—some will remain stable or even
improve over time while others will develop other
types of dementia.4–6 Clinical subtypes of MCI
have been suggested that are assumed to represent
different underlying aetiologies. These subtypes are
based on the cognitive domains in which the
impairment occurs (amnestic versus non-amnestic)
and the number of cognitive domains affected
(single versus multiple).5 The amnestic type of
MCI is regarded as a prodromal form of AD
whereas the subtypes with impairment in non-
memory domains are assumed to represent pro-
dromal stages of other types of dementia, such as
vascular dementia or dementia with Lewy
bodies.5 7 Preliminary studies have shown that
MCI subtypes may indeed represent different
disorders.7 8
Several studies have investigated underlying
brain pathology in MCI subtypes, using MRI. In
all studies, subjects with single domain or multiple
domain amnestic MCI were characterised by
medial temporal lobe atrophy (MTA). MTA on
MRI is a sensitive diagnostic marker for AD.9–12 The
presence of MTA in amnestic MCI has been shown
to be predictive of AD.6 13 14 In non-amnestic MCI,
conflicting findings have been reported. One study
reported MTA to be present in non-amnestic MCI3
while another study did not find this.15 White
matter hyperintensities (WMH) were more com-
mon in non-amnestic MCI compared with amnes-
tic MCI16 although this was not found in another
study.17 WMH, which are generally viewed as
evidence of small vessel disease, are commonly
observed on MRI across the cognitive spectrum.17–22
No studies have yet investigated the interaction
between MTA and WML in subtypes of MCI. This
interaction might be of interest as WML and MTA
may have an additive effect on cognitive function.23
In order to provide further support for the idea
that the subclassification of MCI may differentiate
between various underlying aetiologies, we inves-
tigated the presence of MTA and WMH, and their
combination, across MCI subtypes. Subjects were
classified into four groups: (1) subjective com-
plaints; (2) non-amnestic MCI; (3) single domain
amnestic MCI; and (4) multiple domain amnestic
MCI, based on neuropsychological test perfor-
mance. We hypothesised that MTA would be
mainly associated with amnestic MCI whereas
WMH might be more involved in non-amnestic
MCI. We also investigated whether the prevalence
of MTA and WMH in MCI subtypes was
dependent on age, educational level and sex,
because population based studies have shown that
older age, female sex and low educational level are
associated with an increased risk for dementia.24
METHODS
Study design
Subjects were selected from the DESCRIPA study
(www.descripa.eu), a multicentre study of the
European Alzheimer’s Disease Consortium, aiming
to develop clinical criteria and screening guidelines
for AD in the pre-dementia stage. A detailed
outline of the DESCRIPA study has been described
earlier.25 Inclusion criteria were: age 55 years or
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older, new referral for the evaluation of cognitive complaints
and no diagnosis of dementia. Exclusion criteria were: any
somatic, psychiatric or neurological disorder that may have
caused the cognitive impairment such as a cerebrovascular
accident or strategic infarction with an acute onset of the
cognitive impairment, neurodegenerative diseases such as
Parkinson’s disease, severe head trauma, brain tumour, a history
of alcohol abuse and severe depression. The study closely
followed regular clinical practice or was performed as part of a
research project. For the present study, subjects were selected
from 10 centres in which MRI scanning was part of clinical
practice or a research project (n = 512). MRI was available for
351 (69%) subjects. Reasons for no MRI included: contra-
indication for MRI, patient refusal, poor quality of MRI scan
and avoidance of waiting lists for MRI assessment. Subjects
with and without MRI did not differ with respect to
demographic characteristics, score on the Mini-Mental State
Examination (MMSE)26 or prevalence of vascular risk factors.
Twenty-two subjects who could not be classified as one of
the MCI subtypes because of missing data for one or more
neuropsychological tests were excluded. These subjects scored
lower on MMSE (mean (SD)): 25 (4) (t =25.0, df = 346,
p,0.001, MMSE scores were missing for one of these 22
subjects and for two subjects of the final sample) and a lower
prevalence of hyperlipidaemia (14%; x2 = 4.8, df = 1, p = 0.03)
compared with the rest of the cohort. There were no differences
with respect to age, level of education and prevalence of other
risk factors. The final study sample consisted of 329 subjects.
The study was approved by the local medical ethics committee
in each centre.
Baseline clinical assessment
All subjects underwent a standard battery of examinations,
including a clinical history, medical and neurological examina-
tion, laboratory tests, functional evaluation using the Clinical
Dementia Rating scale,27 rating scales for depression and
neuropsychiatric symptoms, a neuropsychological test battery
(see below) and neuroimaging. General cognition was assessed
using the MMSE. The following vascular risk factors were
included in the analyses: hypertension (systolic blood pressure
.140 mm Hg or diastolic blood pressure .90 mm Hg, a history
of hypertension or use of antihypertensive medication), a
history of diabetes mellitus, hyperlipidaemia and atherosclerosis
(a history of ischaemic heart disease, carotid stenosis, cerebro-
vascular incident or transient ischaemic attack in the past).
Neuropsychological examination
In each centre, a battery of neuropsychological tests was
performed to assess cognitive performance in the domains of
memory, language, executive function and attention, and
visuoconstruction. The tests used to assess each domain could
vary between centres. Raw scores were converted to age,
education and gender corrected z scores according to locally
collected normative data or published normative data and these
z scores were used for further analysis.
Definition of MCI subtypes
Subjects were classified into four MCI subtypes on the basis of
the performance on tests in the cognitive domains of memory,
language, executive function and attention, and visuoconstruc-
tion, as described below. Subjects without impairment in any
domain were classified as subjective complaints, subjects
with impairment in one or more non-memory domains as
non-amnestic MCI, subjects with isolated impairment in the
memory domain as single domain amnestic MCI and subjects
with impairment in the memory domain and at least one other
domain as multiple domain amnestic MCI. Impairment was
defined as a z score of 21.5 or lower, which equals a score of
1.5 SD below the average score of healthy control subjects after
correction for age, sex and education.
Due to variability in the neuropsychological test protocol, the
tests used to define MCI subtypes varied between centres. We
selected in each centre one test for each domain that was
identical or similar to tests used in other centres. The tests to
assess memory were the learning measure and delayed recall
measure of the Rey Auditory Verbal Learning Test (six
centres),28 the word list of the Consortium to Establish a
Registry for AD (CERAD) neuropsychological battery (three
centres)29 and the Selective Reminding Test (one centre).30 The
tests to assess language were 1 min verbal fluency for animals
(nine centres) and 1 min verbal fluency for fruits, animals or car
trades (one centre).31 The test to assess executive function and
attention was the Trail Making Test part A and B (all centres).32
The tests to assess visuoconstruction were the copy subtest of
the Rey–Osterrieth complex figure (six centres),33 the copy of
the CERAD figures (three centres)29 or the copy of figures from
the Mental Deterioration Battery (one centre).34
Thirty-two subjects classified as non-amnestic MCI (34% of
all subjects in this subgroup) had impairments in more than one
non-memory domain and could be considered to have multiple
domain non-amnestic MCI.5 Post-hoc analyses showed no
statistically significant differences with regard to MRI char-
acteristics between subjects with single and multiple domain
non-amnestic MCI, and therefore we analysed the data of
subjects with non-amnestic MCI as a single group.
MRI acquisition
All subjects were studied by MRI within a mean of 0.1 (SD
0.2) years of the baseline clinical assessment. At each site,
subjects were scanned according to the routine MRI protocol,
and consequently the scanners and protocols at different sites
varied. All scanning was performed at 1.0 or 1.5 T and included
a three-dimensional T1 weighted gradient echo sequence and a
fast fluid attenuated inversion recovery (FLAIR) sequence. MRI
data were collected and analysed centrally. Sagittal three-
dimensional T1 weighted images were reformatted in a plane
perpendicular to the long axis of the (left) hippocampus (at a
slice thickness of 2 mm).
Visual rating of MTA and WMH
MTA was rated on coronal T1 weighted images using a 5 point
visual rating scale,12 ranging from 0 (no atrophy) to 4 (severe
atrophy) based on the height of the hippocampal formation and
the surrounding CSF spaces. In the analysis, the average score of
left and right was used, as well as the dichotomised score (MTA
>2 = atrophy). The degree of WMH severity was rated on the
axial FLAIR images using the Age Related White Matter
Changes scale (ARWMC).35 Here we used the total degree of
WMH (range 0–30) by adding the region specific scores of both
hemispheres and a dichotomised score (at the population mean
WMH score: ARWMC.5 = moderate WMH). All visual ratings
were carried out centrally by a single rater (LvdP) who was
blinded to the clinical information. The intra-rater agreement for
the MTA scale was good (kappa 0.68) as well as the intra-rater
agreement for the ARWMC scale, as determined on a test set of 20
MR scans scored twice (weighted kappa 0.95).
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APOE
APOE genotype was determined in a subset of subjects (n = 265,
81%) on genomic DNA extracted from EDTA anticoagulated
blood using the PCR technique. Subjects with data on APOE
genotype had a higher score on the MMSE compared with
subjects with data on APOE genotype (28.1 vs 27.5; p = 0.05)
while age, years of education, gender, systolic blood pressure,
severity of MTA and WMH, and scores on the cognitive tests
did not differ between the groups.
Statistics
SPSS for Windows, V.12.0 (Chicago, Illinois, USA) was used for
data analysis. Characteristics of subjects in the present study
sample were compared with characteristics of excluded subjects
without MRI and missing neuropsychological data using
Student’s t tests or x2 tests when appropriate. Subsequently,
group differences between the MCI subtypes were assessed
using analysis of variance (ANOVA) or logistic regression
models for dichotomous outcome variables. Age and sex were
used as covariates and centre of origin as a categorical covariate.
Bonferroni correction was used to adjust for multiple compar-
isons in the post hoc pairwise comparisons. MTA and WMH
scores were used both in their continuous as well as
dichotomised form (as described in the visual rating section
above). Interactions between MCI subtype and age (dichot-
omised at 70 years), gender and level of education were tested
for severity of MTA and WMH (as continuous variables).
Finally, using both dichotomised MRI measures we computed
a new MTA–WMH categorical variable, yielding four groups:
(1) MTA and WMH absent; (2) MTA absent, WMH present; (3)
MTA present, WMH absent; and (4) MTA and WMH present.
The difference in distribution of subjects over the MTA–WMH
Table 1 Baseline characteristics in the total sample and according to the four MCI subtypes
Total sample
(n = 329)
Subjective
complaints
(n = 77)
Non-amnestic
MCI (n = 93)
Amnestic MCI
Overall
p Value
Group
comparisons
Single domain
(n = 70)
Multiple domain
(n = 89)
Group 1 Group 2 Group 3 Group 4
Demographics
Age (years) 69 (8) 66 (7) 70 (8) 69 (8) 71 (8) ,0.0001 1,2,4
Sex (n (%) female) 188 (57) 39 (51) 64 (69) 31 (44) 54 (61) 0.003 2.3
Education (years) 10 (4) 11 (4) 8 (4) 12 (4) 9 (4) 0.03 2,3
MMSE 28 (2) 28 (2) 28 (2) 28 (2) 27 (2) ,0.0001 1,2,3.4
ApoE4 genotype (n (%))* 126 (48) 27 (45) 27 (35) 34 (58) 28 (41) 0.11 –
Vascular risk factors
Hypertension (n (%)) 216 (66) 48 (63) 62 (67) 45 (65) 61 (69) 0.95 –
Diabetes mellitus (n (%)) 38 (12) 7 (9) 12 (13) 4 (6) 15 (17) 0.28 –
Hyperlipidaemia (n (%)) 122 (38) 21 (28) 36 (40) 27 (40) 38 (44) 0.30 –
Atherosclerosis (n (%)) 45 (15) 8 (11) 13 (15) 12 (18) 12 (15) 0.45 –
MRI
MTA score 1.3 (0.9) 0.8 (0.7) 1.3 (0.8) 1.4 (0.9) 1.7 (0.9) ,0.0001 1,2,3,4; 2,4
MTA present (n (%)) 126 (38) 11 (14) 35 (38) 31 (44) 49 (55) ,0.001 1,2,3, 4
WMH 4.8 (4.9) 3.8 (3.5) 5.3 (5.0) 4.5 (4.5) 5.3 (5.9) 0.21 –
Moderate WMH (n (%)) 105 (32) 20 (26) 36 (34) 22 (31) 27 (30) 0.16 –
Values are expressed as mean (SD) unless stated otherwise. ANOVA or logistic regression models for dichotomous outcome variables with age, sex and centre of origin as
covariates were performed. Bonferonni correction was used to correct for multiple comparisons.
*ApoE genotype was available for 265 subjects: 60 subjective, 77 non-amnestic, 59 amnestic single domain and 69 amnestic multiple domain. Only significant differences are
reported.
MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination (0–30); MTA, medial temporal lobe atrophy; WMH, white matter hyperintensities (0–30), MTA present:
score >2; WMH moderate: score .5.
Figure 1 Bar chart showing the severity
of medial temporal lobe atrophy (MTA) in
each mild cognitive impairment (MCI)
subtype by age group (,70 vs
>70 years). Numbers indicate mean
MTA score (and number of subjects).
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groups across MCI subtypes was assessed using multinomial
logistic regression analysis with MTA–WMH group as the
dependent variable and MCI subtype as a predictor, adjusting
for age.
RESULTS
Table 1 shows the baseline characteristics for the total study
sample and for the four MCI subtypes. Age (p,0.0001), sex
(x2 = 36.1, df = 13, p = 0.028), years of education (p = 0.027)
and MMSE scores (Fp,0.0001) were significantly different
between the groups. There were no differences in APOE
genotype or the prevalence of vascular risk factors across the
MCI subtypes.
Severity of MTA, as reflected by the continuous MTA score,
differed across the MCI subtypes (p,0.001). Pairwise compar-
isons showed that subjects with subjective complaints had less
severe MTA than subjects with non-amnestic MCI (p = 0.047),
single domain amnestic MCI (p = 0.005) and multiple domain
amnestic MCI (p,0.0001), and that subjects with non-amnestic
MCI had less severe MTA compared with subjects with
multiple domain amnestic MCI (p = 0.006). The presence of
MTA >2 increased from 14% of subjects with subjective
complaints to 38% of subjects with non-amnestic MCI, to 44%
in subjects with single domain amnestic MCI and to 55% in
subjects with multiple domain amnestic MCI (post hoc pairwise
comparisons: subjective complaints versus all other subtypes,
p,0.01). In contrast, the total ARWMC score, and the
proportion of subjects with at least moderate WMH
(ARWMC score .5), did not differ across the MCI subtypes.
Correction of the analyses for level of education and vascular
risk factors did not essentially change the results (data not
shown).
The association between the MTA score and MCI subtype
was modified by age, as indicated by a significant interaction
between age (dichotomised at 70 years) and subtype (p = 0.03).
If age was used as a continuous variable, the effect of age on
MTA was also statistically significant. Post hoc analysis showed
that in older subjects, MTA score was strongly associated with
MCI subtype (p,0.0001), in contrast with a weaker association
in younger subjects (p = 0.02) (fig 1).
No significant interaction between MCI subtype and age
group in association with WMH was present (p = 0.19), nor
were there any interactions for gender or level of education and
MCI subtype in association with severity of MTA (p = 0.53 and
p = 0.70) or WMH (p = 0.74 and p = 0.31).
The distribution of four MRI categories, based on the
dichotomised scores of MTA (0–1 vs >2) and WMH (0–5 vs
>6), over the MCI subtypes is shown in fig 2. A multinomial
logistic regression model, adjusted for age, showed that the
distribution of subjects over the four MRI categories differed
between the four MCI subtypes (overall: x2 = 25.7 df = 9,
p = 0.002, Nagelkerke’s R2 = 0.30). Pairwise comparisons
showed that the distribution of subjects over the four MRI
categories differed between subjects with subjective complaints
and the amnestic MCI subtypes (p = 0.023 for single domain
amnestic MCI and p = 0.002 for multiple domain amnestic
MCI) and between non-amnestic MCI and multiple domain
amnestic MCI (p = 0.015). In more detail, in multiple domain
amnestic MCI, a greater proportion of subjects had isolated
MTA versus MTA in combination with WMH compared with
subjects with non-amnestic MCI (p = 0.011). Subjects with
subjective complaints had a greater proportion of subjects with
isolated WMH versus isolated MTA compared with multiple
domain amnestic MCI (p = 0.002). Finally, the proportion of
subjects without any MRI abnormality compared with isolated
MTA was greater in subjective complaints compared with both
types of amnestic MCI (p = 0.004 and p,0.0001, respectively),
and in non-amnestic MCI versus multiple domain amnestic
MCI (p = 0.003). Other pairwise comparisons were not statis-
tically significant.
DISCUSSION
We have provided evidence that the clinical subtypes of MCI,
based on neuropsychological profiles, may have different brain
substrates. Both single and multiple domain amnestic MCI were
associated with more severe MTA in comparison with subjects
with subjective complaints. This is in keeping with previous
studies demonstrating atrophy of the medial temporal lobe in
subjects with amnestic MCI36 37 and may be associated with an
increased risk of development of AD.6 14 However, MTA was
not restricted to amnestic MCI, as a substantial part of subjects
with non-amnestic MCI showed MTA as well. This is in line
with previous longitudinal studies that have shown that a
proportion of subjects with non-amnestic MCI progresses to
Figure 2 Bar chart showing the
distribution of MRI subgroups, based on
the presence of medial temporal lobe
atrophy (MTA) and white matter
hyperintensities (WMH), within the mild
cognitive impairment (MCI) subtypes.
Numbers indicate percentage of subjects
(and number of subjects) within each MCI
subtype.
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clinical AD,7 38 and another MRI study, using voxel based
morphometry, showing varying involvement of the medial
temporal lobe in the non-amnestic (single and multiple domain)
MCI subtypes.3 Alternatively, MTA in non-amnestic MCI may
have a different aetiology and relate to vascular causes.
Our findings are in keeping with a study demonstrating that
subjects with amnestic MCI had a higher prevalence of MTA
than subjects with non-amnestic MCI.15 Two other studies
showed focal atrophy of the medial temporal lobe, including the
hippocampus, in subjects with amnestic MCI in contrast with
subjects with multiple domain MCI, which was associated with
a more diffuse pattern of cortical atrophy.39 40 It is difficult to
compare our results directly, as these studies used different MRI
techniques. In addition, the multiple domain MCI subtype in
these studies included both subjects with impairment in
multiple non-memory domains and in both memory and non-
memory domains. Our study suggests that the classification of
subjects with and without memory impairment into one
subtype may result in a heterogeneous group.
The differences in MTA observed across the MCI subtypes
were largely attributable to subjects aged over 70 years,
suggesting that the concept of MCI subtypes may be less
useful in younger subjects. Our observation may be explained
by the fact that the prevalence of dementia strongly increases
with age,41 and that in subjects with MCI the risk for developing
dementia over a 10 year interval is strongly dependent on age.42
WMH have been reported to be associated with executive
function in MCI43 and control subjects.44 Therefore, we
hypothesised that WMH might be associated with non-
amnestic MCI. However, we could not demonstrate a direct
association between the severity of WMH and any of the MCI
subtypes, in keeping with a recent study.17 Also, the prevalence
of vascular risk factors did not differ across the MCI subtypes.
This is in contrast with the study of Mariani et al who reported
a higher frequency of vascular risk factors and white matter
hyperintensities on MRI in their single non-memory MCI
group.16 The fact that in our study subjects were recruited from
memory clinics and that subjects with a history of stroke were
excluded from the study may have led to an under-representa-
tion of subjects with significant small vessel disease.
Furthermore, the absence of controls subjects did not allow us
to compare the prevalence of WMH with a normal population.
Although MCI subtypes were similar with regard to WMH
severity, differences between combined involvement of MTA
and WMH were observed (fig 2). To our knowledge, this has
not been investigated before. The higher prevalence of MTA in
the amnestic MCI subtypes compared with the other subtypes
was mainly because isolated MTA was more common in
amnestic MCI. This suggests that AD may be the underlying
cause in most amnestic MCI patients with MTA. In non-
amnestic MCI, isolated MTA was relatively rare as most
subjects with MTA also had WMH. As the APOE-e4 allele is a
risk factor for AD, we post hoc investigated whether the
relation of APOE-4 with MTA was different for subjects with
isolated MTA and subjects with MTA and WMH. In the whole
sample, the proportion of APOE e4 carriers in the group with
isolated MTA was higher (29 (53%)) than that in the group
with combined MTA and WMH (16 (33%, p = 0.05)). This
effect was also present in subjects with non-amnestic MCI:
seven (58%) subjects with isolated MTA were APOE-e4 carrier
compared with four (17%) for subjects with MTA and WMH
(p = 0.03). This suggests that in subjects with MTA and WMH,
MTA may have a different pathophysiological background, in
which AD pathology is possibly less relevant. The group of
subjects with subjective complaints has received relatively little
attention in previous studies so far, and the clinical outcome of
these subjects still remains unclear.45 46 In our study, the
majority of subjects categorised as subjective complaints
showed no or few abnormalities on MRI, suggesting that these
subjects are in the earliest stages of a neurodegenerative disease
or that other factors underlie the complaints.
The cross sectional design of our study limits interpretation
about causal mechanisms underlying MRI measures and MCI
subtypes. Another limitation may be the fact that neuropsy-
chological test batteries differed across the various sites,
although this difference may in part be accounted for by
correcting for centre in the analyses. Among the strengths of
this study is the large sample size of MCI subjects with available
MRI scans. All scans were analysed centrally, which reduced the
variability of MRI measures to a large extent. Another strength
of this study is its clinical setting, which makes the results
relevant for clinical practice.
In conclusion, these data provide evidence that the clinical
subtypes of MCI, based on neuropsychological profiles, may
have different brain substrates, especially in older subjects.
However, the observed differences were small and clearly an
overlap of MRI profiles between the MCI subtypes existed.
Further longitudinal analysis is needed to reveal the clinical
outcome of MCI subtypes in relation to MRI measures, which is
important with respect to preventive and possible early
therapeutic interventions in MCI.
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